Patent Landscape and Claims Analysis for U.S. Patent 8,084,483
What Does U.S. Patent 8,084,483 Cover?
U.S. Patent 8,084,483, filed by Merck Sharp & Dohme Corp., was granted on December 27, 2011. The patent primarily relates to methods of treating specific medical conditions, such as autoimmune diseases, using particular chemical compounds.
Scope:
The patent's scope covers novel chemical entities, their pharmaceutical compositions, and methods of their use. The patent claims focus on derivatives of S1P (sphingosine-1-phosphate) receptor modulators, including specific structural features and the method of administering these compounds for therapeutic purposes.
Main Claims:
- Claim 1: A compound of a specified chemical formula, characterized by particular functional groups.
- Claim 2-10: Variations on the chemical structure, detailing substituents and stereochemistry.
- Claim 11: The use of the compounds in treating autoimmune diseases such as multiple sclerosis.
- Claims 12-15: Pharmaceutical compositions containing the compounds, including dosage forms and formulations.
The claims emphasize chemical structure specificity, method of treatment, and pharmaceutical composition, typical of medicinal patents.
Patent Claim Details
Scope of Claim Language
- The core claims are directed at a class of sphingosine-1-phosphate receptor modulators with defined stereochemistry and substituents.
- Claims specify chemical formulas with particular positions for substituents (e.g., R1, R2, R3), enabling coverage of a broad set of derivatives.
- The method claims focus on treating autoimmune conditions using compounds within this class.
Claims Breadth and Limitations
The claims are moderately broad, encompassing variations in substituents and stereochemistry, but are limited to compounds falling within the defined structural formula. The patent claims exclude other chemical classes of S1P modulators, such as non-structurally related compounds.
Strengths and Limitations
Strengths:
- Claims cover key derivatives that are therapeutically relevant.
- Use claims for autoimmune diseases increase patent utility beyond the compound alone, enhancing market exclusivity for specific indications.
Limitations:
- Structural claims may be vulnerable if prior art discloses similar compounds.
- Use-specific claims can be challenged if previous therapies targeting S1P receptors are prior art.
Patent Landscape Analysis
Related Patents and Patent Families
Merck holds several related patents covering S1P receptor modulators, including:
- US 7,981,379 (granted 2011): Focused on specific S1P receptor agonists.
- US 8,516,031: Covering compositions and dosing methods.
- Patent families in Europe (EP Patent 2,466,951) and Asia (JP 2014-502467) expand protection scope.
Competitor Patents
Other pharmaceutical companies such as Novartis and Bristol-Myers Squibb hold competing patents related to S1P receptor modulators:
- Novartis' patent EP 2,203,261: Covers fingolimod derivatives.
- Bristol-Myers Squibb's patent US 9,072,096: Focused on alternative receptor modulators.
Patent Expiration and Market Competition
The '483 patent expires in 2029, creating a window for generic entry starting around 2028. Patent landscape indicates a crowded environment with overlapping patents, potentially complicating generic development and approval.
Patent Litigation and Challenges
Possible challenges to the patent include:
- Invalidity claims based on prior art disclosures of similar compounds.
- Non-infringement assertions if competitors develop structurally distinct S1P modulators.
No reported litigations explicitly contesting U.S. Patent 8,084,483 as of the latest data (2023), but ongoing patent applications may impact its enforceability.
Key Market and R&D Insights
- The patent covers a promising class of drugs targeting autoimmune conditions like multiple sclerosis.
- Competition from generic manufacturers could significantly impact market share post-2029.
- Licensing opportunities include collaborations with biotech firms working on complementary S1P receptor modulators.
Key Takeaways
- U.S. Patent 8,084,483 protects a specific chemical class of S1P receptor modulators with method-of-treatment claims.
- The patent scope covers multiple derivatives, providing strong IP protection but with potential vulnerability to prior art challenges.
- Several related patents from Merck and competitors define an extensive patent landscape in this therapeutic area.
- Expiration post-2029 will likely lead to increased generic competition.
- Patent validity may face challenges based on prior art, but no known litigations challenge this patent as of 2023.
5 FAQs
Q1: What is the primary therapeutic focus of the patent?
A1: The patent covers compounds for treating autoimmune diseases, including multiple sclerosis.
Q2: How broad are the claims in this patent?
A2: The claims are structurally specific but cover a range of derivatives within defined chemical formulas.
Q3: Who are the main competitors in this IP landscape?
A3: Novartis, Bristol-Myers Squibb, and other pharma firms hold related patents on S1P receptor modulators.
Q4: When does the patent expire?
A4: The patent expires in 2029.
Q5: What are key risks to patent exclusivity?
A5: Prior art challenges, overlapping patents, and possible patent invalidity claims threaten exclusivity.
References
- U.S. Patent and Trademark Office. (2011). Patent No. 8,084,483.
- Chappey, D., et al. (2012). Sphingosine-1-phosphate receptor modulators: Chemistry, biology, and therapeutic potential. Expert Opinion on Therapeutic Patents, 22(4), 417-431.
- European Patent Office. (2014). EP 2,466,951.
- Novartis AG. (2011). EP 2,203,261.
- Bristol-Myers Squibb. (2017). U.S. Patent No. 9,072,096.
